The Cell Biology Core provides major resources to the program project investigators, including normal human cells, an extensive library of characterized melanoma cell lines, patient-derived xenografts, and multiple models to study specific biological processes (Objective 1). The melanoma cell line library encompasses >400 cell lines, at least 200 with known genetic status. To exclude cross-contamination, all experimental cell lines are fingerprinted. Our normal cell panel includes: melanocytes, keratinocytes, fibroblasts, endothelial cells, and skin-derived stem cells. Other resources include adenoviral and lentiviral vectors for growth factors, adhesion molecules, and oncogenes and monoclonal antibodies to melanoma associated biomarkers Three-dimensional cultures of normal human skin (skin equivalents or organotypic cultures of skin) with a dermis of fibroblasts embedded in collagen and an epidermis of melanocytes/melanoma cells and keratinocytes, are also continuously available to the program investigators. This three-dimensional model is superior to standard cell culture techniques because it mimics the in vivo microenvironment for the melanocytes/melanoma cells. For screening studies the Core is providing a robotics-assisted spheroid culture model that allows investigations on melanoma cells displaying in vivo relevant architecture, cell-to cell contacts and invasion, in the presence of a collagen support matrix. The Core additionally provides subcutaneous melanoma growth models for standard experiments, including patient-derived xenografts that are exclusively maintained in vivo and using tissues provided by the Pathology Core B. For Objective 2, the Core will test compounds developed and selected for further analysis and has the knowledge and infrastructure for performing high-throughput screening both in two- and three-dimensional cultures. The responsibility of the Core is to test compounds in an expanded number of cell lines and in quality control testing through different biological assays. For Objective 3, the Core is available to train investigators of the Program in all biological assays and models. Overall, this Core will provide efficient and high quality service to all laboratories within this Program Project.
This core supports the research projects with cell- and animal-based experimental tools and models, but also conducts experiments. The infrastructure encompasses libraries of human melanoma cell lines, viruses and antibodies, skin and tumor growth models, each reflecting different aspects of melanoma biology in patients. Most recent developments have added the capacity of the core to conduct high-throughput screening of compounds to identify novel inhibitors.
|Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4|
|Budina-Kolomets, Anna; Webster, Marie R; Leu, Julia I-Ju et al. (2016) HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res 76:2720-30|
|Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24|
|Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30|
|Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :|
|Grasso, Michael; Estrada, Michelle A; Ventocilla, Christian et al. (2016) Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol 11:2876-2888|
|Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3DÂ melanoma models. Pigment Cell Melanoma Res 29:317-28|
|Jennis, Matthew; Kung, Che-Pei; Basu, Subhasree et al. (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918-30|
|Chatwichien, Jaruwan; Basu, Subhasree; Budina-Kolomets, Anna et al. (2016) PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric Î²-carboline. Bioorg Med Chem Lett 26:4884-4887|
|Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602|
Showing the most recent 10 out of 87 publications